Diabetic kidney disease is the leading cause of end-stage kidney disease in high-income countries. The strict control of glycemic oscillations is the principal therapeutic target, but this could be hard to achieve in uremic patients due to their unpredictable insulin sensitivity. Currently, the evaluation of the glycemic profile relies on serum markers (glycated hemoglobin HbA1c, glycated albumin, and fructosamine), capillary glucose blood control (self-monitoring of blood glucose), and interstitial glucose control (continue glucose monitoring). We conducted a systematic review of published articles on continue glucose monitoring in hemodialysis patients with type 2 diabetes, which included 12 major articles. Four studies found significant fluctuations in glucose levels during hemodialysis sessions. All studies reported a higher mean amplitude of glucose variations on the hemodialysis day. Three studies agreed that continue glucose monitoring is better than glycated hemoglobin in detecting these abnormalities. Moreover, continue glucose monitoring was more accurate and perceived as easier to use by patients and their caregivers. In patients with type 2 diabetes on hemodialysis, glucose levels show different variation patterns than the patients on hemodialysis without diabetes. Considering manageability, accuracy, and cost-effectiveness, continue glucose monitoring could be the ideal diagnostic tool for the patient with diabetes on hemodialysis.

Continuous glucose monitoring in patients with type 2 diabetes on hemodialysis / M. Gallieni, C. De Salvo, M.E. Lunati, A. Rossi, F. D'Addio, I. Pastore, G. Sabiu, R. Miglio, G.V. Zuccotti, P. Fiorina. - In: ACTA DIABETOLOGICA. - ISSN 0940-5429. - 58:8(2021 Aug), pp. 975-981. [10.1007/s00592-021-01699-6]

Continuous glucose monitoring in patients with type 2 diabetes on hemodialysis

M. Gallieni
Primo
;
C. De Salvo;M.E. Lunati;A. Rossi;F. D'Addio;I. Pastore;G. Sabiu;R. Miglio;G.V. Zuccotti
Penultimo
;
P. Fiorina
Ultimo
2021

Abstract

Diabetic kidney disease is the leading cause of end-stage kidney disease in high-income countries. The strict control of glycemic oscillations is the principal therapeutic target, but this could be hard to achieve in uremic patients due to their unpredictable insulin sensitivity. Currently, the evaluation of the glycemic profile relies on serum markers (glycated hemoglobin HbA1c, glycated albumin, and fructosamine), capillary glucose blood control (self-monitoring of blood glucose), and interstitial glucose control (continue glucose monitoring). We conducted a systematic review of published articles on continue glucose monitoring in hemodialysis patients with type 2 diabetes, which included 12 major articles. Four studies found significant fluctuations in glucose levels during hemodialysis sessions. All studies reported a higher mean amplitude of glucose variations on the hemodialysis day. Three studies agreed that continue glucose monitoring is better than glycated hemoglobin in detecting these abnormalities. Moreover, continue glucose monitoring was more accurate and perceived as easier to use by patients and their caregivers. In patients with type 2 diabetes on hemodialysis, glucose levels show different variation patterns than the patients on hemodialysis without diabetes. Considering manageability, accuracy, and cost-effectiveness, continue glucose monitoring could be the ideal diagnostic tool for the patient with diabetes on hemodialysis.
Chronic kidney disease; Continuous glucose monitoring; Diabetes mellitus; Hemodialysis;
Settore MED/13 - Endocrinologia
ago-2021
20-mar-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
Gallieni. Continuous_Glucose_Monitoring_hemodialysis. Acta Diabetol 2021.pdf

accesso aperto

Descrizione: Online first
Tipologia: Publisher's version/PDF
Dimensione 567.57 kB
Formato Adobe PDF
567.57 kB Adobe PDF Visualizza/Apri
Gallieni2021_Article_ContinuousGlucoseMonitoringInP.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 562.09 kB
Formato Adobe PDF
562.09 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/826632
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 8
social impact